MK-4440
Total Payments
$255,433
Transactions
19
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $255,433 | 19 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $255,433 | 19 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b Study of ARQ 751 as a Single Agent or in Combination with Other Anti-cancer Agents in Adult Subjects with Advanced Solid Tumors with PIK3CA,AKT,PTEN Mutations | Merck Sharp & Dohme Corporation | $255,433 | 0 |
Top Doctors Receiving Payments for MK-4440
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dallas, TX | $255,433 | 19 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $255,433
Product Information
- Type Drug
- Total Payments $255,433
- Total Doctors 0
- Transactions 19
About MK-4440
MK-4440 is a drug associated with $255,433 in payments to 0 healthcare providers, recorded across 19 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2020 to 2020. In 2020, $255,433 was paid across 19 transactions to 0 doctors.
The most common payment nature for MK-4440 is "Unspecified" ($255,433, 100.0% of total).
MK-4440 is associated with 1 research study, including "A Phase 1b Study of ARQ 751 as a Single Agent or in Combination with Other Anti-cancer Agents in Adult Subjects with Advanced Solid Tumors with PIK3CA,AKT,PTEN Mutations" ($255,433).